Inactive Instrument

Analyst Reco. Qiagen NV Nasdaq

Equities

QIAGEN NV : Deutsche Bank reiterates its Buy rating	Apr. 16	ZD
QIAGEN NV : UBS reaffirms its Neutral rating	Mar. 01	ZD
Morgan Stanley Upgrades Qiagen to Overweight From Equalweight, Adjusts Price Target to $49.48 From $51	Feb. 16	MT
QIAGEN NV : Berenberg reiterates its Buy rating	Feb. 16	ZD
QIAGEN NV : Deutsche Bank remains its Buy rating	Feb. 14	ZD
QIAGEN NV : JP Morgan reiterates its Buy rating	Feb. 08	ZD
QIAGEN NV : UBS reiterates its Neutral rating	Feb. 08	ZD
QIAGEN : In line Q4; routine business prospects remain intact	Feb. 07
QIAGEN NV : Gets a Neutral rating from UBS	Feb. 07	ZD
QIAGEN NV : Berenberg reaffirms its Buy rating	Feb. 07	ZD
QIAGEN NV : DZ Bank gives a Buy rating	Feb. 07	ZD
QIAGEN NV : Deutsche Bank reiterates its Buy rating	Feb. 07	ZD
BofA Securities Raises Price Target on Qiagen to $55 From $52, Maintains Buy Rating	Jan. 29	MT
QIAGEN NV : Buy rating from Deutsche Bank	Jan. 26	ZD
QIAGEN NV : Berenberg reiterates its Buy rating	Jan. 18	ZD
QIAGEN NV : Morgan Stanley keeps its Buy rating	Jan. 08	ZD
QIAGEN NV : UBS reiterates its Neutral rating	Jan. 05	ZD
QIAGEN NV : UBS sticks Neutral	Jan. 03	ZD
UBS Ups Price Target on Qiagen to $44 From $42, Keeps Neutral Rating	Jan. 02	MT
QIAGEN NV : Gets a Buy rating from JP Morgan	Dec. 19	ZD

No results for this search

QIAGEN : In line Q4; routine business prospects remain intact

February 07, 2024 at 10:30 am EST